{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:41:01Z","timestamp":1763811661445,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jiac.2025.102728","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T20:30:45Z","timestamp":1748723445000},"page":"102728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season"],"prefix":"10.1016","volume":"31","author":[{"given":"Naoki","family":"Kawai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Ikematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Bando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woon Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maeda","family":"Tetsunari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Echizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102728_bib1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102728_bib2","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102728_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102728_bib4","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1056\/NEJMoa2115926","article-title":"Protection against covid-19 by BNT162b2 booster across age groups","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102728_bib5","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102728_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S2213-2600(22)00407-6","article-title":"Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study","volume":"11","author":"Yechezkel","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"10318","key":"10.1016\/j.jiac.2025.102728_bib7","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"10318","key":"10.1016\/j.jiac.2025.102728_bib8","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2025.102728_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/vaccines12020118","article-title":"Safety and immunogenicity of the monovalent omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals \u226512 Years old: a phase 2\/3 trial","volume":"12","author":"Gayed","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jiac.2025.102728_bib10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102728_bib11","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102728_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa2213082","article-title":"Bivalent omicron BA.1-Adapted BNT162b2 booster in adults older than 55 years","volume":"388","author":"Winokur","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102728_bib13","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMc2402779","article-title":"Durability of XBB.1.5 vaccines against omicron subvariants","volume":"390","author":"Lin","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102728_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza Vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiac.2025.102728_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza Vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: a phase 2, randomised, open-label study","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiac.2025.102728_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32813","article-title":"Immunogenicity and reactogenicity of coadministration of COVID-19 and influenza vaccines","volume":"6","author":"Gonen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiac.2025.102728_bib17","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.vaccine.2022.02.025","article-title":"Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine","volume":"40","author":"Tani","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2025.102728_bib18","article-title":"No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19","volume":"X","author":"Tani","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2025.102728_bib19","doi-asserted-by":"crossref","first-page":"ofac493","DOI":"10.1093\/ofid\/ofac493","article-title":"Correlation of post-vaccination fever with specific antibody response to severe acute respiratory syndrome coronavirus 2 BNT162b2 booster and No significant influence of antipyretic medication","volume":"9","author":"Tani","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2025.102728_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100489","article-title":"Reduction of adverse reactions and correlation between post-vaccination fever and specific antibody response across successive SARS-CoV-2 mRNA vaccinations","volume":"18","author":"Tani","year":"2024","journal-title":"Vaccine X"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:48:59Z","timestamp":1762368539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1341321X25001254"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102728","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102728"}}